Skip to main content

Sharing at least one photo a day? Chances are that you're a millennial.

2015: RISE OF THE MILLENNIALS
Highlights of The Internet Trends Report

The internet is abuzz. Mary Meeker, dubbed the Internet Whisperer, has released the 2015 Internet Trends Report, and it highlights some interesting points about millennials and their smartphones.

 

Speaking of smartphones, we have listed a few tips on how to boost your Android. Enjoy!


The Opera Newsletter team

 
5 apps to boost your android
Try these free apps that help you tweak your phone for a custom feel.
 
Read more
save 2 seconds per minute online
Save time online with customized keyboard shortcuts. Here's how.
Read more
MEGABYTES AND PHONE BILLS
What do you know about about megabytes and mobile data?
Read more
internet trends show opera mini is among top apps in india

Opera Mini's data-saving technology provides a solution in the congested Indian networks, helping people to browse faster.
Read more
our products
About Opera
Opera products enable more than 350 million internet consumers to discover and connect with the content and services that matter most to them, no matter what device, network or location.
Contact us
http://forums.opera.com Gjerdrums vei 19
NO-0484 OSLO
NORWAY
Social media
© 2015 Opera Software ASA. All Rights Reserved

 
Unsubscribe   /    Send to a friend
 






This email was sent to dbtech.hp.alert@blogger.com
why did I get this?    unsubscribe from this list    update subscription preferences
Opera Software · Gjerdrums vei 19, Oslo, Norway · Oslo, Oslo 0484 · Norway

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More